BRPI0517650A - uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca - Google Patents

uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca

Info

Publication number
BRPI0517650A
BRPI0517650A BRPI0517650-6A BRPI0517650A BRPI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A BR PI0517650 A BRPI0517650 A BR PI0517650A
Authority
BR
Brazil
Prior art keywords
remodeling
ranolazine
heart failure
reversal
combination
Prior art date
Application number
BRPI0517650-6A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Naief Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of BRPI0517650A publication Critical patent/BRPI0517650A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

USO DE RANOLAZINA EM COMBINAçáO COM PELO MENOS UM AGENTE DE REMODELAMENTO PARA REVERSAO DE REMODELAMENTO VENTRICULAR ESQUERDO NO TRATAMENTO DE INSUFICIêNCIA CARDìACA. A presente invenção se refere a um método de reversão do remodelamento do ventrículo esquerdo através de administração combinada de quantidades terapeuticamente eficazes de ranolazina e pelo menos um agente de coremodelamento, o qual pode ser um inibidor de ACE, um ARB ou um beta-bloqueador. O método encontra utilidade no tratamento de insuficiência cardíaca. A presente invenção também se refere à formulações farmacêuticas que são adequadas para tal administração combinada.
BRPI0517650-6A 2004-11-09 2005-11-09 uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca BRPI0517650A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09
PCT/US2005/040824 WO2006053161A1 (en) 2004-11-09 2005-11-09 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Publications (1)

Publication Number Publication Date
BRPI0517650A true BRPI0517650A (pt) 2008-10-14

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517650-6A BRPI0517650A (pt) 2004-11-09 2005-11-09 uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca

Country Status (15)

Country Link
US (2) US20060111361A1 (pt)
EP (1) EP1809289A1 (pt)
JP (1) JP2008519770A (pt)
KR (1) KR20070084063A (pt)
CN (1) CN101072562A (pt)
AU (1) AU2005304421A1 (pt)
BR (1) BRPI0517650A (pt)
CA (1) CA2586840A1 (pt)
IL (1) IL183056A0 (pt)
MX (1) MX2007005367A (pt)
NO (1) NO20072934L (pt)
RU (1) RU2007121707A (pt)
SG (1) SG156681A1 (pt)
WO (1) WO2006053161A1 (pt)
ZA (1) ZA200703697B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
AU2007292926A1 (en) * 2006-09-08 2008-03-13 Symphony Medical, Inc. Intramyocardial patterning for treating localized anomalies of the heart
CA2670651A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
CA2678515A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
AU2008239681B2 (en) * 2007-04-11 2013-10-03 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
ES2402675T3 (es) * 2007-05-31 2013-05-07 Gilead Palo Alto, Inc. Ranolazina para el péptido natriurético de tipo cerebral a niveles elevados
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2018053504A1 (en) 2016-09-19 2018-03-22 Abiomed, Inc. Cardiovascular assist system that quantifies heart function and facilitates heart recovery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE80710B1 (en) * 1989-06-23 1998-12-16 Syntex Inc Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
WO2001060348A2 (en) * 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
US20060111361A1 (en) 2006-05-25
ZA200703697B (en) 2008-09-25
AU2005304421A1 (en) 2006-05-18
CA2586840A1 (en) 2006-05-18
MX2007005367A (es) 2007-06-18
CN101072562A (zh) 2007-11-14
WO2006053161A1 (en) 2006-05-18
WO2006053161A8 (en) 2006-09-14
RU2007121707A (ru) 2008-12-20
IL183056A0 (en) 2007-10-31
KR20070084063A (ko) 2007-08-24
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
EP1809289A1 (en) 2007-07-25
NO20072934L (no) 2007-08-08
JP2008519770A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
AR119158A1 (es) Tratamientos de angioedema hereditario
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
ECSP055525A (es) Inhibidores de cinasas de tirosina
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
NO20064584L (no) Tetrahydropyridoindolderivater
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
NO20024646D0 (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
CO2022000270A2 (es) Inhibidores de enzimas
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BRPI0703970A2 (pt) tratamento de pacientes psiquiátricos com função hepática reduzida com paliperidona
CO5570661A2 (es) Combinaciones que comprenden inhibidores de cox-2 y aspirina
BR0015039A (pt) Método para administrar um inibidor fosfodiesterase 4
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
WO2010074731A3 (en) Nail fungus treatment and composition
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.